On April 26, Beqvez (fidanacogene elaparvovec-dzkt) won approval to treat some adults with moderate-to-severe hemophilia B. The drugmaker set the list price at $3.5 million, a company spokesperson told CNBC. Another hemophilia B gene medication, Hemgenix, costs the same.
In a phase 3 study of 45 patients, researchers found a decrease in annualized bleeding rates among those who received the medication, which was well-tolerated.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.